Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID‐19

To compare adverse outcomes among COVID‐19 patients with pre‐existing type 2 diabetes (T2D) only, T2D and cardiovascular disease (CVD), or neither.

[1]  B. Carter,et al.  Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis , 2022, Endocrinology, diabetes & metabolism.

[2]  E. Huang,et al.  Summary of Revisions: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[3]  K. Khunti,et al.  Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews , 2021, Diabetes Care.

[4]  Meeta Gupta,et al.  A Systematic Review and Meta-analysis of Diabetes Associated Mortality in Patients with COVID-19 , 2021, International journal of endocrinology and metabolism.

[5]  G. Lip,et al.  Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews , 2021, European heart journal. Quality of care & clinical outcomes.

[6]  Haiyan Yang,et al.  A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity , 2021, BMC Public Health.

[7]  N. Sharif,et al.  Prevalence and impact of diabetes and cardiovascular disease on clinical outcome among patients with COVID-19 in Bangladesh , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[8]  N. Sattar,et al.  Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study , 2021, The Lancet Regional Health - Europe.

[9]  E. Ekinci,et al.  An overview of COVID‐19 in people with diabetes: Pathophysiology and considerations in the inpatient setting , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[10]  L. Zajdenverg,et al.  Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis , 2020, Diabetology & Metabolic Syndrome.

[11]  K. Khunti,et al.  Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study , 2020, The Lancet Diabetes & Endocrinology.

[12]  P. Valensi,et al.  Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era , 2020, Diabetes Care.

[13]  T. Einarson,et al.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.

[14]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[15]  Stephen V Faraone,et al.  Interpreting estimates of treatment effects: implications for managed care. , 2008, P & T : a peer-reviewed journal for formulary management.

[16]  J. Avorn,et al.  Variable selection for propensity score models. , 2006, American journal of epidemiology.

[17]  D. Rubin,et al.  Combining Propensity Score Matching with Additional Adjustments for Prognostic Covariates , 2000 .

[18]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[19]  U.S. Census Bureau , 2009 .